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ABSTRACT 
 
 
Atherosclerotic cardiovascular disease prediction model 
and prescribing rates of Statins: 
the Korean Heart Study 
 
Jung, Keum Ji 
Dept. of Public Health 
The Graduate School 
Yonsei University 
 
Background and Aims: The aims of the study were to evaluate the performance 
of the American College of Cardiology/American Heart Association (ACC/AHA) 2013 
Pooled Cohort Equations in the Korean Heart Study (KHS) population, to develop a 
Korean Risk Prediction Model (KRPM) for atherosclerotic cardiovascular disease 
(ASCVD) events, and to evaluate the relation between 10-year ASCVD risk score from 
two different ASCVD prediction equations and actual statin prescriptions in the last 10 
years (2004-2013) in Korean general population. 
Methods: The KHS cohort included 200,010 Korean adults aged 40–79 years 
who were free from ASCVD at baseline. Discrimination and calibration of the 
ACC/AHA 2013 Pooled Cohort Equations in predicting 10-year ASCVD risk in the KHS 
cohort were evaluated. Recalibration of the ACC/AHA Equations was done using 
vii 
 
 
 
coefficients from the pooled cohorts' Cox model but mean values of risk factors and 
ASCVD incidence rates from the KHS cohort. The KRPM was derived using coefficients, 
mean risk factor values, and mean incidences from the KHS cohort. Per equations, we 
also calculated the prescribing rates of statins using cumulative incidence. 
Results: In the discriminatory analysis, the ACC/AHA Equations for either 
White or African-American (AA) moderately distinguished cases from non-cases in the 
KHS cohort, and were similar to the KRPM: For men, the area under the receiver 
operating characteristic curve (AUROCs) were 0.727 (White model), 0.725 (AA model), 
and 0.741 (Korean model); for women, the AUROCs were 0.738, 0.739, and 0.745, 
respectively. Absolute 10-year ASCVD risk for men in the KHS cohort was 
overestimated by 56.5% in the White model and 74.1% in the AA model, while the risk 
for women was underestimated by 27.9% in the White model and overestimated by 
29.1% in the AA model. Recalibration of the ACC/AHA Equations did not affect 
discriminatory ability but improved calibration substantially, especially in men in the 
White model. Of the three ASCVD risk prediction models, the KRPM showed the best 
calibration, with the lowest Hosmer-Lemeshow X
2
 for both men and women when used 
in a validation subsample. During the follow-up period, an overall prescribing rate of 
statins in women was 33.5% greater than that of men, 26.3%. 
Conclusions: The ACC/AHA Equations
 
should not be directly applied for 
ASCVD risk prediction in a Korean population. The KRPM showed best predictive 
ability for ASCVD risk. Therefore, utilization of the prediction risk score in deciding on 
preventive statin therapy is suggested for Korean population.  
 
keywords: Prediction, Statin, Atherosclerotic cardiovascular disease, Cohort study 
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I. INTRODUCTION 
 
 In 2013, the Risk Assessment Work Group (Work Group) appointed by the 
National Heart, Lung, and Blood Institute released the risk assessment tool for initial 
atherosclerotic cardiovascular disease (ASCVD) events, defined as the occurrence of 
coronary death or fatal stroke or the first occurrence of nonfatal myocardial infarction 
(MI) or stroke (Third Report of the National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III) Final Report. 2002; Grundy et al. 2004; Goff et al. 
2014). To estimate the 10-year risk of developing a first ASCVD event, American 
College of Cardiology/American Heart Association (ACC/AHA) Equations were 
developed using data from large epidemiological studies (n = 24,626) conducted in the 
US (Atherosclerosis Risk in Communities, Cardiovascular Health Study, Coronary 
Artery Risk Development in Young Adults, and the Framingham and Framingham 
Offspring studies) (Goff et al. 2014). These Pooled Cohort Equations provide sex- and 
race-specific estimates of the 10-year risk of ASCVD for African-American and White 
men and women 40 to 79 years of age (Goff et al. 2014). However, the Work Group has 
recognized that data are limited for follow-up of Hispanic and Asian-American cohorts 
and specifically called for further research that includes ―analyses of short- and long-term 
risk in diverse groups....‘‖ (Goff et al. 2014). Subsequently, several cohort (Kavousi et al. 
2014; Muntner et al. 2014; DeFilippis et al. 2015) and cross-sectional (Blaha et al. 2014; 
Ford et al; 2014; Kandula et al. 2014; Lee 2014, Oh et al. 2014) studies have applied the 
ACC/AHA 2013 Pooled Cohort Equations in different populations, with varying results. 
The direct application of this American assessment tool in other non-US populations is 
2 
 
 
 
questionable, particularly in Asian populations such as Korea, where there are possible 
differences in genetics as well as ASCVD risk factors and event rates (Jee et al. 2014; 
Kim et al. 2014). However, experience from the Framingham risk prediction algorithms 
for coronary heart disease (CHD) showed that the Framingham functions, when 
recalibrated, had improved predictive ability for several different ethnic groups in the US 
(D‘Agostino et al. 2001; Liu et al. 2004) and China (Liu et al. 2004).  
 In Korea, the Korean Heart Study (KHS) for cardiovascular disease has 
conducted a 10-year follow-up and successfully developed a CHD risk prediction model 
which used the Framingham risk prediction algorithms as starting point (Jee et al. 2014). 
The Korean experience provides the opportunity to examine the performance of the 
original and recalibrated ACC/AHA 2013 Pooled Cohort Equations as a 10-year ASCVD 
risk assessment tool. 
 Also, according to the ACC/AHA 2013 guidelines, statin therapy is 
recommended if the subject‘s 10-year ASCVD risk exceeds 7.5% (Stone et al. 2014; 
Goff et al. 2014; Kavousi et al. 2014; Muntner et al, 2014), and roughly two-thirds of the 
US adults may be eligible for statins (Kavousi et al. 2014). However, studies assessing its 
applicability in an Asian population-wide setting or association between statins and 10-
year ASCVD risk score are scarce. Furthermore, as Asian population including Korean 
lacks a representative ASCVD risk tool, in-depth analysis of the last 10-year statin 
prescriptions and evaluation of ASCVD risk models are necessary. The results of this 
study may be used as a baseline data to guide implementation of policy measuring the 
adequacy of therapy for dyslipidemia and ASCVD high risk groups among the general 
population. 
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II. OBJECTIVES 
 
 The objectives of this study were to evaluate the performance of the ACC/AHA 
2013 Pooled Cohort Equations in the KHS population, to develop a Korean Risk 
Prediction Model (KRPM) for ASCVD, and to evaluate the relation between 10-year 
ASCVD risk score from two different ASCVD prediction equations and actual statin 
prescriptions in the last 10 years (2004-2013) in Korean general population. 
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III. MATERIALS AND METHODS 
 
A. Study population 
 
 Study members are participants in routine health assessments at health promotion 
centers across South Korea. The centers are used by members of the public following 
referral by themselves, their family physician, their employer, or upon recommendation 
by a family member or friend. Of 80 health promotion centers in South Korea, around 
half routinely store their records electronically; of these, 18 agreed to provide data (Jee et 
al. 2014). Participating centers were generally geographically representative of the 
country with the exception of the South West where there was no participating centers. 
The South Korean population is assigned a personal identification number at birth. This 
number facilitated linkage with hospital admission records and death registers. All 
Koreans are members of the National Health Insurance Service (NHIS), formerly, the 
Korean Medical Insurance Corporation and National Health Insurance Corporation. To 
ensure anonymity, all linkages were carried out by NHIS staff. The record linkage 
resulted in 430,920 study members (164,138 women) aged 30–74 years at health 
assessment at baseline between 1996 and 2004. According to the Bioethics and Safety 
Act (no. 7159) from the Ministry of Health and Welfare in January, 2005, a retrospective 
study was performed using the data collected from participants who underwent medical 
examinations before December 2004 (participants without written consent). 
 First, in a study to develop a KPRM, all enrollees of the health centers aged 75-
79 years (N=1,670) were included while those aged 30-39 (N=123,868) were excluded, 
thus corresponding to the age range of the ACC/AHA 2013 Pooled Cohort Equations 
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which was 40-79 years (Goff et al. 2014). The baseline period of this study was 1996 to 
2001 for the development of a 10-year ASCVD risk prediction model. Therefore, all 
participants had a minimum of 10 or more potential years of follow-up by the end of 
December 2012 (Figure 1). Among the participants with at least 10 years follow-up, 
individuals who were receiving lipid-lowering medication at baseline (n = 8,809), those 
with stroke or cardiovascular disease (n =10,066), or those with missing values of 
essential variables (n =4,234) such as blood pressure, total serum cholesterol, high 
density cholesterol, fasting serum glucose, smoking status, or body mass index were 
excluded. The study ultimately included 192,605 individuals (114,622 men and 77,983 
women).  
 Second, in a comparing the two models, all enrollees of the health centers aged 
75-79 years (N=1,670) were included while those aged 30-39 (N=123,868) were 
excluded, thus corresponding to the age range of the ACC/AHA 2013 Pooled Cohort 
Equations which was 40-79 years (Goff et al. 2014). Among the 308,722 participants, 
individuals who were receiving lipid-lowering medication at baseline (n = 19,364) were 
excluded. Then, 289,358 participants had a minimum of 9 or more potential years of 
follow-up by the end of December 2013. For analyses on examining the ASCVD event, 
CVD mortality, and prescribing rates of statins, exclusions were made using the criteria 
from each equation (Figure 2). 
The Institutional Review Board of Human Research of Yonsei University 
approved the study (IRB approval number 4-2007-0065). Data for this study were 
collected from routine health examinations and therefore no written content was 
necessary. 
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Figure 1. Flow chart describing study population, KHS 
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Figure 2. Inclusion and exclusion criteria for the KHS for assessment of different ASCVD risk prediction equations 
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B. Data collection 
 
 Participants were interviewed using a structured questionnaire to collect 
information on personal history of cigarette smoking (current, former, never) and 
physician diagnosis of significant chronic diseases (diabetes, hypertension, stroke, 
myocardial infarction, angina). A registered nurse or medical technician measured blood 
pressure using a standard mercury/automatic sphygmomanometer. A 12-hour fasting 
blood sample was taken and a clinical chemistry assay of fasting glucose, lipid profiles, 
and other biomarkers were measured with a COBAS INTEGRA 800 and a 7600 
Analyzer (Hitachi, Tokyo, Japan). In all risk assessments, diabetes was defined as fasting 
serum glucose >126 mg/dL or diabetic treatment history; hypertension was systolic blood 
pressure ≥140 mmHg or use of hypertension medication; and former smoker was 
classified as non-smoker.  
 
C. Outcome variables 
 
 First ―hard‖ ASCVD events, comprising the occurrence of death from CHD or 
fatal stroke or the first occurrence of nonfatal myocardial infarction or stroke, were 
recorded (Goff et al. 2014). The events among the study cohort were identified from 
insurance claims reported to the National Health Insurance System (NHIS). Since the 
NHIS is a national organization, follow-up was expected to be 100% complete. We 
ascertained nonfatal MI or stroke events, defined according to the International 
Classification of Diseases 10
th
 (ICD-10) Revision, from health insurance claims data 
from the NHIS. Cases of fatal ASCVD, including deaths from CHD (ICD-10, I20-I25), 
9 
 
 
 
and deaths from stroke (ICD-10, I63), were ascertained from the cause of death listed on 
death certificates.  
 A validation study has been conducted by the Korean Society of Cardiology 
through the formation of the Event Validation Committee (July 2008 to May 2009). For 
participants who provided written permission for the use of their personal information, 
673 CHD events between 1994 and 2007 were confirmed with individual hospital 
medical records, and 73% of the cases of myocardial infarction were validated (Kimm et 
al. 2012). The updated validation study was improved to 93% of MI events between 2008 
and 2011 (Kim 2013). Another study reported that 83% of stroke diagnoses were 
validated among a sample of 626 stroke patients (Park et al. 2000). 
 Actual prescription of statins was followed-up by the end of December 2013. 
Statins use was defined by investigating prescription frequency of the following drugs: 
atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin. 
We evaluated proportion of individuals for whom statins subscribed as cumulative 
incidence and prescribing rate per 100 person-years. 
 
 
D. Statistical analysis 
 
i. Evaluation of the ACC/AHA 2013 Pooled Cohort Equations for 10-year 
ASCVD risk prediction 
 
 The predictive ability of the ACC/AHA 2013 Pooled Cohort Equations for the 
KHS population was evaluated based on discrimination and calibration of the models for 
both White and African-American men and women. Discrimination is the capability to 
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categorize those with and without disease based on predictive values. Calibration is the 
measure of how accurately the predicted risk matched the observed risk. For all analyses, 
follow-up was censored at 10 years. 
a) Discrimination: The discriminatory power of the ACC/AHA model in predicting 
ASCVD end points among the KHS participants was assessed by using the area under the 
receiver operating characteristic curve (AUROC) or c statistic (Pencina et al. 2004).  
b) Calibration: A calibration analysis, which measured how closely the predicted risk fit 
the actual risk, was conducted by dividing participants, within each sex, into deciles of 
predicted risk. The observed and predicted 10-year ASCVD risks in each decile were 
compared using the Hosmer–Lemeshow test. Calibration was also determined graphically 
by plotting the observed and predicted ASCVD events, grouped according to deciles of 
predicted probabilities (Nam 2000).  
 
ii. Recalibration of the ACC/AHA Pooled Cohort Equations to the KHS 
population 
 
 The ACC/AHA 2013 Pooled Cohort Equations were recalibrated for the KHS 
population following the method proposed by D‘Agostino et al (2001) (D‘Agostino et 
al.2001). In the recalibrated ACC/AHA Equations, the coefficients were taken from the 
ACC/AHA Equations‘ Cox model, but the risk factors in the ACC/AHA Equations were 
replaced by the mean values of the risk factors from KHS cohort, while the ACC/AHA 
average incidence rate S0(t) was replaced by the KHS cohort‘s own average incidence 
rate.  
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iii. Development of the KPRM for ASCVD 
 
 For the KRPM, coefficients in the KHS Cox proportional hazard models, mean 
values of the risk factors, and mean incidences in the KHS cohort were used. Risk scores 
for this ASCVD Risk Prediction Model were developed by Cox proportional hazard 
models derived in men and women after testing for the assumptions underlying its use. 
We stratified the cohort data into 2 groups: a 50% random sampling (development data 
set) for model development and the remaining 50% (test data set) for internal validation 
(Figure 1). The predictive ability of the KRPM for the KHS population was assessed 
based on discrimination and calibration of the models in the test dataset.  
 To ensure comparability with the ACC/AHA 2013 Pooled Cohort Equations, age, 
blood pressure, total and HDL-cholesterol levels, diabetes, and smoking status were 
considered for inclusion in the Korean ASCVD risk score. In terms of blood pressure, 
cases were classified into treated and untreated. Contemporary guidelines (Goff et al. 
2014) were used to define diabetes as self-reported or fasting glucose ≥126 mg/dL.  
 
iv. Sensitivity analysis 
 
 Discrimination and calibration analyses of the KRPM were repeated by 
excluding subjects with diabetes or low density lipoprotein levels >190mg/dl. 
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v. Actual statin prescriptions in the last 10 years (2004-2013) 
 
 Both cumulative incidence and prescribing rates of statins per 100 person-years 
were calculated. Using Kaplan-Meier method, cumulative incidence of statins was 
expressed as proportions of individuals who subscribed statins in overall, before, and 
after the 1
st
 ASCVD event during follow-up.  
 
 All analyses were conducted using SAS version 9.1.2 (SAS Institute Inc., Cary, 
NC, USA). 
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IV. RESULTS 
 
A. General characteristics of study population 
 
 Overall, mean ages of KHS participants were similar among men (50.13 years; 
SD 7.94) and women (51.81 years; SD 8.12). Mean systolic blood pressure values were 
also similar between the sexes. However, smoking was highly prevalent in men (49.40%) 
but uncommon in women (4.49%) (Table 1).  
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Table 1. General characteristics of study to develop a KPRM participants aged 40–79 Years from the KHS (1996–2004), N=200,010 
 
 
Men 
(N=119,715) 
Women 
(N=80,295) 
 Mean (SD) Mean (SD) 
Age, year 50.13 (7.94) 51.81 (8.12) 
Body Mass Index, kg/m
2
 23.84 (2.69) 23.72 (3.03) 
Total cholesterol, mg/dL 196.84 (34.79) 201.22 (37.44) 
HDL-cholesterol, mg/dL 47.98 (10.88) 54.23 (12.83) 
LDL-cholesterol, mg/dL 120.14 ( 32.54) 123.59 (34.04) 
Systolic blood pressure, mmHg 124.79 (17.61) 124.49 (20.30) 
Insurance premium, Korean won* 145,449 (158,873) 131,308 (142,791) 
 % % 
Statin use   4.25 2.88 
Smoking status   
Ex smokers 26.46 4.10 
Current smokers 49.40 4.49 
Diabetes
† 
(Yes) 10.49 7.43 
Regular exercise (Yes) 53.15 39.35 
* A measure of socioeconomic status was the health insurance premium per year, in South Korean ‗Won‘ (1,129 Won = 1.00 US Dollar).  
†
 Diabetes was defined as fasting serum glucose ≥126 mg/dL or a history of treatment for diabetes. 
KRPM, Korean Risk Prediction Model; KHS, Korean Heart Study; SD, standard deviation; HDL, high-density lipoprotein; LDL, low-density lipoprotein;
15 
 
 
 
B. ASCVD incidence 
 
 During the mean 12.8 years of follow-up, 12,327 ASCVD events (including 
2,175 nonfatal MI, 478 fatal CHD, 10,049 nonfatal stroke, and 749 fatal stroke) occurred 
among the study participants (Table 2). The ASCVD incidences per 100,000 person-
years were 765.7 for men and 721.5 for women. Among the total stroke events, ischemic 
stroke accounted for 58.5% among men and 52.2% among women.  
Compared with the regression coefficients from the KHS for similar variables, 
the published regression coefficients for the ACC/AHA Equations differed in values but 
had the same directions (Table 3 and 4). 
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Table 2. Person-years of follow-up and ASCVD events in men and women aged 40–79 years from the KHS (1997–2012), 
N=192,605§ 
 
 Men (n=114,622) Women (n=77,983) 
 
Person-Years 
of Follow-up 
Events 
Incidence per 
100,000 PY* 
Person-Years 
of Follow-up 
Events 
Incidence per 
100,000 PY* 
  Total ASCVD 1,441,296 7,669 765.7 1,046,510 4,658 721.5 
Nonfatal myocardial infarction 1,469,872 1,718 144.4 1,027,594 457 74.0 
Fatal coronary heart disease 1,479,886 357 38.7 1,030,249 121 35.5 
Nonfatal stroke 1,450,495 5,874 598.9 1,008,014 4,175 627.7 
 Ischemic stroke 1,459,375 3,585 372.8 1,017,659 2,256 380.7 
 Hemorrhagic stroke 1,471,817 1,258 120.1 1,025,569 876 116.4 
Fatal stroke 1,479,886 480 68.0 1,030,249 269 61.2 
 Ischemic stroke 1,479,886 133 24.4 1,030,249 64 20.3 
Hemorrhagic stroke 1,479,886 209 24.6 1,030,249 126 20.8 
§ Excluded for statin use at baseline  
* Incidences were standardized to the age distribution in the 2005 Korean population  
ASCVD, atherosclerotic cardiovascular disease; KHS, Korean Heart Study
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Table 3. Equation parameters of the KHS model and the ACC/AHA 2013 Pooled Cohort Equations for estimation of 10-year risk 
for ASCVD events in men Aged 40–79 Years 
 
 KHS Model ACC/AHA (W)  KHS Model ACC/AHA (AA) 
 Mean Coefficient (SE) Coefficient  Mean Coefficient (SE) Coefficient 
Ln Age 3.902 10.212 (2.333) 12.344  3.902 3.970 (0.076) 2.469 
Ln Total cholesterol 5.263 7.916 (1.639) 11.853  5.263 0.692 (0.066) 0.302 
Ln Age * Ln Total cholesterol 20.538 -1.806 (0.409) -2.664  - - - 
Ln HDL-cholesterol 3.847 -4.346 (1.283) -7.990  3.847 -0.590 (0.051) -0.307 
Ln Age * Ln HDL-cholesterol 15.014 0.936 (0.319) 1.769  - - - 
Ln Treated SBP 0.262 2.037 (0.082) 1.797  0.262 2.041 (0.080) 1.916 
Ln Untreated SBP 4.555 2.011 (0.081) 1.764  4.555 2.013 (0.081) 1.809 
Current smoker 0.496 2.519 (0.590) 7.837  0.496 0.449 (0.024) 0.549 
Ln Age * Current smoker 1.923 -0.517 (0.147) -1.795  - - - 
Diabetes
†
 0.101 0.409 (0.030) 0.658  0.101 0.412 (0.030) 0.645 
Baseline Survival  0.96394 0.9144   0.96346 0.8954 
KHS, Korean Heart Study; ACC/AHA, American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; 
Ln, natural log; HDL, high-density lipoprotein; SBP, systolic blood pressure; SE, standard error; W, white; AA, African–American 
†
 Diabetes was defined as fasting serum glucose ≥126 mg/dL or history of treatment for diabetes 
 
18 
 
 
 
Table 4. Equation parameters of the KHS model and the ACC/AHA 2013 Pooled Cohort Equations for estimation of 10-year risk 
for ASCVD events in women aged 40–79 years 
 
 KHS Model ACC/AHA (W)  KHS Model ACC/AHA (AA) 
 Mean Coefficient (SE) Coefficient  Mean Coefficient (SE) Coefficient 
Ln Age 3.935 -16.121 (4.905) -29.799  3.935 11.000 (3.654) 17.114 
Ln Age square 15.507 2.518 (0.561) 4.884  - - - 
Ln Total cholesterol 5.284 1.812 (2.242) 13.540  5.284 0.272 (0.084) 0.940 
Ln Age * Ln Total cholesterol 20.801 -0.368 (0.554) -3.114  - - - 
Ln HDL-cholesterol 3.965 -2.325 (1.692) -13.578  3.965 -1.269 (1.732) -18.920 
Ln Age * Ln HDL-cholesterol 15.600 0.455 (0.418) 3.149  15.600 0.199 (0.428) 4.475 
Ln Treated SBP 0.329 1.698 (0.096) 2.019  0.329 8.078 (2.547) 29.291 
Ln Age * Ln Treated SBP - - -  1.326 -1.577 (0.629) -6.432 
Ln Untreated SBP 4.483 1.643 (0.098) 1.957  4.483 8.179 (2.610) 27.820 
Ln Age * Ln Untreated SBP - - -  17.616 -1.616 (0.644) -6.087 
Current smoker 0.045 1.446 (1.446) 7.574  0.045 0.444 (0.063) 0.691 
Ln Age * Current smoker 0.177 -0.253 (0.358) -1.665  - - - 
Diabetes
†
 0.072 0.427 (0.042) 0.661  0.072 0.426 (0.042) 0.874 
Baseline Survival  0.96928 0.9665   0.97001 0.9533 
KHS, Korean Heart Study; ACC/AHA, American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; 
Ln, natural log; HDL, high-density lipoprotein; SBP, systolic blood pressure; SE, standard error; W, white; AA, African–American 
†
 Diabetes was defined as fasting serum glucose ≥126 mg/dL or history of treatment for diabetes 
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C. ACC/AHA 2013 Pooled Cohort Equations 
 
 In the discriminatory analysis, the ACC/AHA Equations for either White or 
African-American (AA) men moderately distinguished cases from non-cases in the KHS 
cohort. For men, the AUROCs were 0.727 (95% Confidence Interval (CI), 0.721–0.734) 
using the White model and 0.725 (95% CI, 0.718–0.731) using the AA model. For 
women, the AUROCs were 0.738 (95% CI, 0.729–0.746) using the White model and 
0.739 (95% CI, 0.731–0.747) using the AA model (Figure 3).  
However, in calibration, the ACC/AHA Equations statistically overestimated the 
event rates observed in the KHS cohort. For men, the Hosmer–Lemeshow X2 was 
1,364.26 for the White model (P < 0.001) and 2,059.60 for the AA model (P < 0.001). 
For women, the Hosmer–Lemeshow X2 was 683.12 for the White model (P < 0.001) and 
604.83 for the AA model (P < 0.001; Figure 3). Absolute 10-year ASCVD risk for men 
in the KHS cohort was overestimated by 56.5% in the White model and 74.1% in the AA 
model, while the risk for women was underestimated by 27.9% in the White model and 
overestimated by 29.1% in the AA model. For men, larger differences were observed in 
higher deciles of predicted risk, particularly in the AA model. For example, in the 10
th
 
decile in men, the predicted rate was about 23% while the actual rate was only about 
16%. 
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Figure 3. Ten-year probability of predicted and actual ASCVD events in men and women from the KHS using the ACC/AHA 
2013 Pooled Cohort Equations for White (W) and African-American (AA) 
ASCVD, atherosclerotic cardiovascular disease; KHS, Korean Heart Study; ACC/AHA, American College of Cardiology/American Heart Association 
W, ―White equation‖ of new ACC/AHA equations; AA, ―African–American equation‖ of new ACC/AHA equations. 
W: Calibration for χ2: 1,364.26, P < 0.0001; AA: Calibration for χ2: 2,059.60, P < 0.0001 for men  
W: Calibration for χ2: 683.12 P < 0.0001; AA: Calibration for χ2: 604.83, P < 0.0001 for women.
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D. Recalibrated ACC/AHA 2013 Pooled Cohort Equations 
 
 Recalibration did not affect the discriminatory ability of the ACC/AHA 
Equations but improved calibration substantially, especially in men in the White model. 
The X
2
 was 110.25 for men (P < 0.001) and 439.50 for women (P < 0.001) (Figure 4). 
The largest difference between the actual and predicted rates after recalibration was 1.7% 
(in the 10
th
 decile in men) compared with the difference of 8.75% for the direct 
ACC/AHA Equations. The recalibrated ACC/AHA 2013 pooled cohort equations are 
given in Appendix A. 
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Figure 4. Ten-year probability of predicted and actual ASCVD events in men and women from the KHS using the recalibrated 
ACC/AHA 2013 Pooled Cohort Equations for White (W) and African-American (AA) 
ASCVD, atherosclerotic cardiovascular disease; ACC/AHA, American College of Cardiology/American Heart Association; KHS, Korean Heart Study 
W, ―White equation‖ of new ACC/AHA equations; AA, ―African–American equation‖ of new ACC/AHA equations. 
W: Calibration for χ2: 110.25, P < 0.0001; AA: Calibration for χ2: 221.49, P < 0.0001 for men  
W: Calibration for χ2: 439.50, P < 0.0001; AA: Calibration for χ2: 694.77, P < 0.0001 for women
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E. KRPM for ASCVD 
 
 In the discriminatory analysis, the AUROCs for men and women were 0.734 
(95% CI, 0.727–0.740) and 0.741 (95% CI, 0.733–0.750) (Table 5), respectively, 
showing good ability to distinguish cases from non-cases. Regarding calibration, the 
Hosmer–Lemeshow X2 was 25.90 for men (P = 0.002) and 14.69 for women (P = 0.100), 
showing that the actual ASCVD rates in the KHS cohort were similar to the event rates 
predicted by the KRPM (Figure 5). The KRPM algorithm is given in Appendix B. 
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Table 5. Equation parameters of the KRPM in men and women aged 40–79 Years from the KHS (1997–2012) 
 
KRPM, Korean Risk Prediction Model; KHS, Korean Heart Study; Ln, natural log; HDL, High-density lipoprotein; SBP, systolic blood pressure; SE, standard error; AUC, 
Area Under the receiver operation characteristic Curve 
† 
Diabetes was defined as fasting serum glucose >126 mg/dL or diabetic treatment history
 Men  Women 
 KRPM ACC/AHA (White) ACC/AHA (AA)  KRPM ACC/AHA (White) ACC/AHA (AA) 
 Coefficient (SE)  Coefficient (SE) 
Ln Age 9.36 (4.41) 10.21 (2.33) 3.97 (0.08)  -9.52 (4.73) -16.12 (4.91) 11.00 (3.65) 
Ln Age square 2.42 (0.42) - -  3.42 (0.58) 2.52 (0.56) - 
Ln Total cholesterol 6.41 (1.60) 7.92 (1.64) 0.69 (0.07)  0.32 (0.08) 1.81 (2.24) 0.27 (0.08) 
Ln Age * Ln Total cholesterol -1.43 (0.40) -1.81 (0.41)   - -0.37 (0.55) - 
Ln HDL-cholesterol -3.84 (1.26) -4.35 (1.28) -0.59 (0.05)  -0.48 (0.06) -2.32 (1.69) -1.27 (1.73) 
Ln Age * Ln HDL-cholesterol 0.81 (0.31) 0.94 (0.32) -  - 0.46 (0.42) 0.20 (0.43) 
Ln Treated SBP 18.59 (2.00) 2.04 (0.08) 2.04 (0.08)  13.40 (2.58) 1.70 (0.10) 8.08 (2.55) 
Ln Age * Ln Treated SBP -4.12 (0.50) - -  -2.89 (0.64) - -1.58 (0.63) 
Ln Untreated SBP 18.54 (2.00) 2.01 (0.08) 2.01 (0.08)  13.29 (2.63) 1.64 (0.10) 8.18 (2.61) 
Ln Age * Ln Untreated SBP -4.11 (0.50) - -  -2.88 (0.65) - -1.62 (0.64) 
Current smoker 2.46 (0.60) 2.52 (0.59) 0.45 (0.02)  0.42 (0.06) 1.45 (1.45) 0.44 (0.06) 
Ln Age * Current smoker -0.50 (0.15) -0.52 (0.15) -  - -0.25 (0.36) - 
Diabetes
†
 0.41 (0.03) 0.41 (0.03) 0.41 (0.03)  0.42 (0.04) 0.43 (0.04) 0.43 (0.04) 
Baseline Survival 0.96427 0.96394 0.96346  0.96963 0.96928 0.97001 
AUC 0.734(0.727-0.740) 0.732(0.725-0.739) 0.731(0.725-0.738)  0.741(0.733-0.750) 0.741(0.733-0.749) 0.741(0.733-0.749) 
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Figure 5. Ten-year probability of predicted and actual ASCVD events in men and women from the KHS using the KRPM 
ASCVD, atherosclerotic cardiovascular disease; KHS, Korean Heart Study; KRPM, Korean Risk Prediction Model;  
Calibration for χ2: 25.90, P = 0.002 for men; 14.69, P = 0.100 for women
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F. Sensitivity Analysis 
 
 In the sensitivity analyses, the AUROCs for the subset of men and women 
without diabetes & LDL>70 mg/dL or LDL>190 mg/dL were not significantly different 
from the whole study population (Table 6). 
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Table 6. Equation parameters of the KRPM in men and women aged 40–79 years from the KHS (1997–2012) excluding subjects with 
LDL >190 mg/dL, or diabetes & LDL >70mg/dL 
KRPM, Korean Risk Prediction Model; KHS, Korean Heart Study; Ln, natural log; HDL, High-density lipoprotein; LDL, Low-density lipoprotein; SBP, systolic blood pressure; 
SE, standard error; AUC, Area Under the receiver operation characteristic Curve 
† 
Diabetes was defined as fasting serum glucose >126 mg/dL or diabetic treatment history
 Men  Women 
 KRPM ACC/AHA (White) ACC/AHA (AA)  KRPM ACC/AHA (White) ACC/AHA (AA) 
 Coefficient (SE)  Coefficient (SE) 
Ln Age 8.32 (4.63) 10.38 (2.48) 4.00 (0.08)  -11.53 (4.93) -18.20 (5.15) 12.15 (3.83) 
Ln Age square 2.55 (0.44) - -  3.83 (0.61) 2.81 (0.58) - 
Ln Total cholesterol 6.66 (1.72) 8.25 (1.75) 0.63 (0.07)  0.35 (0.09) 1.65 (2.41) 0.30 (0.09) 
Ln Age * Ln Total cholesterol -1.51 (0.43) -1.91 (0.44) -  - -0.32 (0.60) - 
Ln HDL-cholesterol -4.16 (1.32) -4.73 (1.35) -0.60 (0.05)  -0.50 (0.07) -1.90 (1.75) -0.73 (1.80) 
Ln Age * Ln HDL-cholesterol 0.89 (0.33) 1.03 (0.34) -  - 0.34 (0.43) 0.06 (0.45) 
Ln Treated SBP 18.29 (2.10) 2.03 (0.08) 2.04 (0.08)  14.47 (2.69) 1.69 (0.10) 8.53 (2.67) 
Ln Age * Ln Treated SBP -4.05 (0.52) - -  -3.16 (0.66) - -1.69 (0.66) 
Ln Untreated SBP 18.36 (2.14) 2.00(0.09) 2.01 (0.09)  14.35 (2.74) 1.63 (0.10) 8.64 (2.73) 
Ln Age * Ln Untreated SBP -4.07 (0.53) - -  -3.14 (0.68) - -1.73 (0.68) 
Current smoker 2.29 (0.63) 2.39 (0.62) 0.45 (0.02)  0.36 (0.07) 1.70 (1.53) 0.39 (0.07) 
Ln Age * Current smoker -0.49 (0.16) -0.49 (0.16) -  - -0.33 (0.38) - 
Diabetes
†
 0.47 (0.04) 0.47 (0.04) 0.47 (0.04)  0.39 (0.06) 0.39 (0.06) 0.40 (0.06) 
Baseline Survival 0.96595 0.96567 0.96521  0.97111 0.97072 0.97149 
AUC 0.730(0.723-0.738) 0.729(0.722-0.736) 0.729(0.721-0.736)  0.740(0.731-0.748) 0.739(0.730-0.748) 0.739(0.730-0.748) 
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G. Actual statin prescriptions in the last 10 years (2004-2013)  
 
 Baseline characteristics of the participants are presented in Table 7. Overall, 
mean ages of the Korean Heart Study participants were similar among men (50.2 years) 
and women (52.0 years). Mean systolic blood pressure values were also similar between 
the sexes. However, smoking was highly prevalent in men (48.2%) but uncommon in 
women (4.2%).  
During the mean follow-up of 10.5 years, 14,010 ASCVD events (2,175 nonfatal 
MI, 528 fatal CHD, 11,649 nonfatal stroke, and 827 fatal stroke) occurred among the 
study participants (Figure 2). The ASCVD incidence per 100,000 person-years was 464 
for men and 410 for women. For total stroke events, ischemic stroke accounted for 58.5% 
of men and 52.2% of women. 
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Table 7. General characteristics of the comparing the two models study participants aged 40 to 79 from the KHS (1996-2004), 
N=308,722 
 
Men 
(N=185,010) 
Women 
(N=123,712) 
 Mean (SD) Mean (SD) 
Age, years 50.20 (8.10) 51.98 (8.25) 
Body mass index, kg/m
2
 23.98 (2.73) 23.76 (3.05) 
Systolic blood pressure, mmHg 124.55 (17.53) 123.68 (20.29) 
Diastolic blood pressure, mmHg 79.07 (11.78) 75.96 (12.31) 
Total cholesterol, mg/dL 196.93 (34.92) 200.54 (37.39) 
HDL-cholesterol, mg/dL 48.16 (10.98) 54.54 (12.78) 
LDL-cholesterol, mg/dL 120.09 (32.89) 123.66 (34.32) 
Insurance premium, Korean won* 144,354 (155,187) 125,207 (138,318) 
   
 % % 
Current smoking  48.18 4.23 
Diabetes 
† 
(Yes) 10.79 7.51 
Prevalent ASCVD 4.29 5.80 
Antihypertensive treatment (Yes) 6.97 8.22 
Statin treatment at baseline (Yes) 5.60 7.31 
* A measure of socioeconomic status was the health insurance premium per year, in South Korean ‗Won‘ (1,129 Won = 1.00 US Dollar)   
KHS, Korean Heart Study; HDL, high density lipoprotein; LDL, low density lipoprotein; SD, standard deviation 
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 Figure 6 and 7 shows cumulative incidence of statin use among three groups: no 
ASCVD event, before ASCVD event, and after ASCVD event during follow-up. For the 
two equations, statin prescriptions showed a proportional increase with 10-year ASCVD 
risk category among all groups in men and women (P for trend <0.0001).  
Prescribing rates of statins in healthy men and women were 21.9% and 29.9%. 
Using ACC/AHA equations, 61.6% and 51.2% of men and women had no statin therapy 
for primary prevention even at risk score of ≥7.5%. Using KRPM equations, 62.3% and 
51.8% of men and women had no statin therapy for primary prevention even at risk score 
of ≥7.5%. 
The overall ASCVD risk score using KRPM equations showed moderate 
association with prescribing rates. 
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10-y predicted risk category, % 
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No. of participants with: 
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7,789 (354)        68,395 (8,090)     24,171 (4,314)    39,387 (9,427) 
   385 (63)           6,345 (1,615)       3,898 (1,174)    14,148 (4,514) 
   385 (74)           6,345 (1,915)       3,898 (1,412)    14,148 (5,657) 
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10-y predicted risk category, % 
No event Before event After event
% 
No. of participants with: 
  no event (statin) 
  before event (statin) 
  after event (statin) 
41,454 (4,932)     39,947 (11,076)       4,758 (1,661)      4,897 (1,724) 
  2,584 (534)         7,860 (2,657)         2,120 (801)      3,452 (1,209) 
  2,584 (618)          7,860 (3,117)        2,210 (953)      3,452 (1,510) 
 
 
Figure 6. Prescribing rate of statins in relation to ASCVD events by risk score the ACC/AHA 2013 Pooled Cohort Equations 
among the KHS participants, 2004-2013 
ASCVD, atherosclerotic cardiovascular disease; ACC/AHA, American College of Cardiology/American Heart Association; KHS, Korean Heart Study 
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10-y predicted risk category, % 
No event Before event After event
% 
No. of participants with: 
  no event (statin) 
  before event (statin) 
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9,077 (466)         94,270 (13,459)      17,592 (3,923)    18,803 (4,336) 
  414 (71)           10,418 (2,967)         4,667 (1,529)      9,277 (2,801) 
  414 (80)           10,418 (3,555)         4,667 (1,863)      9,277 (3,560) 
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10-y predicted risk category, % 
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No. of participants with: 
  no event (statin) 
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  after event (statin) 
9,126 (629)          63,883 (12,827)       9,648 (3,066)     8,399 (2,871)     
   346 (44)            7,333  (2,197)         3,217 (1,143)     5,120 (1,817) 
   346 (57)            7,333  (2,571)         3,217 (1,339)     5,120 (2,231) 
 
 
Figure 7. Prescribing rate of statins in relation to ASCVD events by risk score KRPM among the KHS participants, 2004-2013 
ASCVD, atherosclerotic cardiovascular disease; KRPM, Korean Risk Prediction Model; KHS, Korean Heart Study 
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V. DISCUSSION 
 
 The Work Group of the ACC/AHA 2013 Risk Assessment Guideline, in their 
published guideline (Goff et al. 2014), recognized the knowledge gaps in ASCVD risk 
assessment and recommended further research to assess ASCVD risk in diverse groups. 
In the present analysis, we tested the performance of the ACC/AHA 2013 Pooled Cohort 
Equations in a large Korean population over 200,000 participants, both directly and after 
recalibration was compared them with the performance of functions derived from the 
Korean cohort itself to determine the absolute 10-year risk of ASCVD. We used both the 
ACC/AHA White and African-American Equations separately to assess their predictive 
value. 
 The present study provides evidence that the ACC/AHA Equations are not 
directly applicable in the Korean population and should be used with caution in 
populations whereas the risk estimator developed by the authors may provide a valuable 
tool for predicting 10-year ASCVD risk in the Korean population. Despite good 
discrimination, the 2013 ACC/AHA Equations largely overestimated absolute ASCVD 
risk among Korean men in particular, resulting in predicted ASCVD events that were 
twice as high as the observed ASCVD events in our study population since the incidence 
rate of ASCVD among Korean is low. Patterns of environmental exposures as well as 
genetic background also vary between the Korean population and the US population of 
the ACC/AHA model. For example, prevalence of obesity is significantly lower among 
Korean adults than US adults. These differing rates of ASCVD incidence and associated 
risk factors may be the reason the ACC/AHA Pooled Cohort Equations do not calibrate 
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well in our study population. On the other hand, the KRPM developed for this study may 
be a valuable tool for predicting 10-year ASCVD risk in the Korean population. 
 Also, in this cohort of healthy men and women, without previous prescription of 
statins and history of ASCVD, CVD, chronic kidney disease, or diabetes, we found that 
19.7% of men and 24.4% of women had newly prescribed stains over 10 year follow-up 
period. However, we found that 75.3% of men and 72.8% of women with ASCVD had 
no prescription of stains prior to ASCVD event during the follow-up. Of two equations, 
ACC/AHA and KRPM equations, 10-year ASCVD risk using KRPM equations showed 
good predictability with actual ASCVD event in Korean population. However, 10-year 
ASCVD risk score using ACC/AHA equations showed slightly stronger associations 
with actual prescribing rates of statins in Korean population than those using KRPM 
equations. 
 Various studies that had evaluated the ACC/AHA 2013 Pooled Cohort Equations 
in different populations found overestimation of risk. In a commentary by Ridker and 
Cook, the study authors used the ACC/AHA Equations and compared their estimates 
with observed event rates in three large primary prevention cohorts—the Women's 
Health Study, the Physicians' Health Study, and the Women's Health Initiative 
Observational Study—and found that the ACC/AHA risk assessment tool overestimated 
ASCVD risk by 75–150% (Ridker et al. 2013; Ridker et al 2014). And they reported that 
2013 new ACC/AHA criteria could result in more than 45 million middle-aged 
Americans without CVD (about 33% of American adults) for statin therapy 
recommendation (33,090,000 at ≥7.5% 10-year risk: 12,766,000 at >5.0-7.4% 10-year 
risk) (Ridker et al. 2013; Ridker et al 2014). 
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 There were three validation cohort studies of the ACC/AHA Equations - a cohort 
of black and White US adults aged 45 to 79 years (Muntner et al. 2014), an European 
cohort of Dutch individuals 55 years and older (Kavousi et al. 2014), and the Multiethnic 
Study of Atherosclerosis cohort of US adults aged 50 to 74 (DeFilippis et al. 2015). In a 
cohort study of Black and White US adults aged 45 to 79 years (Muntner et al. 2014), 
Muntner et al evaluated the 5-year risk of ASCVD using the ACC/AHA 2013 Pooled 
Cohort Equations and found poor calibration and overestimation of risk in their primary 
study cohort. However they reported that the ACC/AHA Equations were well calibrated 
in a post-hoc cohort consisting of a subgroup of study participants and subjects >65 years 
identified in the US Centers for Medicare and Medicaid Services which were not 
adjudicated. The limitations of this study included follow-up limited to 5 years to 
evaluate a 10-year risk score as well as the use of unadjudicated events.  
 In a Dutch cohort of White individuals 55 years and older (Kavousi et al. 2014), 
Kavousi et al compared the performance of the ACC/AHA Equations, the Adult 
Treatment Panel III (ATP-III) guidelines and the European Society of Cardiology 
guidelines, and showed an overestimation of ASCVD events by the ACC/AHA guideline, 
which would result in recommendation of statin treatments for nearly all men and two-
thirds of women, proportions exceeding those with the Adult Treatment Panel III (ATP-
III) or the European Society of Cardiology guidelines. In this cohort, the ACC/AHA risk 
prediction model demonstrated modest discrimination and poor calibration (Kavousi et al. 
2014), the latter a reflection of risk overestimation. One limitation of this study was the 
small number of events for certain outcomes. 
 In the Multiethnic Study of Atherosclerosis (MESA) cohort of US adults aged 50 
to 74 (Seo et al. 2014), DeFilippis et al. examined the performance of the ACC/AHA 
Equations and 4 other risk scores, and found that the ACC/AHA Equations overestimated 
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risk for ASCVD events by 86% in men and 67% in women. By their respective end 
points, 3 of those risk scores—Framingham risk score (FRS) for prediction of CHD, FRS 
for prediction of CVD, and ATP-III—also overestimated risk in men and women of this 
MESA cohort. The Reynolds Risk Score, however, overestimated risk in men but 
underestimated risk in women. This result is similar to our observation that the 
ACC/AHA White equation, when applied to the KHS population, underestimated risk in 
Korean women. This unexpected finding deserves further investigation as the potential 
cause is currently not evident. 
 Although the performance of the ACC/AHA Pooled Cohort Equations
 
developed 
by the Work Group remains to be further assessed in other longitudinal populations, the 
present study provides evidence that recalibration of the ACC/AHA Equations
 
resulted in 
marked improvement in predictive ability in the Korean population. In particular, 
recalibrated White-specific functions estimated ASCVD risk well in both Korean men 
and women. If this process is equally successful in other settings, it can be applicable in 
other populations. 
 We previously reported lower CHD rates and risk factor levels in the Korean 
population compared with those in the United States (Jee et al. 2014). The previous 
Framingham CHD model overestimated the CHD risk by approximately 5 to 6 times in 
Koreans (Jee et al. 2014). However, the total stroke rates were comparable with those in 
the United States. In fact, in many developed countries, the incidence of stroke is 
declining even though the actual number of strokes is increasing because of the 
increasingly aging population. While the estimated stroke incidence per 100,000 persons 
is 250 in Korea (Seo et al. 2014) and 390 in Japan (Yatsuya et al. 2013), it is reported to 
be 140 in the United States (Feigin et al. 2009). The incidence of stroke among Asian 
countries was higher than that in the US, suggesting that stroke comprises a large 
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proportion of ASCVD events in the Korean population. Therefore, while a previous 
study on CHD showed the Framingham model estimated that the CHD incidence was 5 
to 6 times higher in Korean men and women (Muntner et al. 2014), the 2013 ACC/AHA 
functions overestimated the incidence of ASCVD by about 2 times higher in Korean men 
and women compared to the 2013 ACC/AHA functions.  
 In the calibration analysis, a systematic overestimation was observed when the 
original ACC/AHA Equations were applied directly to the Korean cohort, especially in 
the higher deciles. One potential cause for the observed overestimation is that the cohorts 
used to derive the ACC/AHA Equations were several decades older than the KHS cohort, 
and consequently the significance of the risk factors included in the risk scores may have 
changed over time. 
 From our findings, the prescribing rates of statins among those with CHD event 
were approximately 75% and 67.3% among middle-aged Korean men and women. A 
survey from 10 Korean educational hospital in 2003 reported 58% prescribing rates of 
lipid lowering drug among CHD patients (Sung et al. 2005). The prescribing rate of lipid 
lowering drug among CHD patients in 2007 was nearly 90% in Korea. The US 2013 
ACC/AHA cholesterol guideline recommends high-intensity statin therapy after acute 
myocardial infarction (AMI) in individuals up to age 75 years for whom there are no 
safety concerns (Stone et al. 2014). Brooks et al. provided strong evidence that providers 
were attempting to individualize statin prescriptions to patients after AMI. In other study, 
GP prescribed statins to only one-fifth of those in the 10-19% risk band usually in 
association with knowing major risk factors. And that study confirmed continuing 
undertreatment of patients at highest CVD risk (≥20%). Policy interventions promoting 
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higher statin-use rates after ASCVD including AMI may still need to be re-evaluated 
with cautions.  
  According to ACC/AHA guidelines, statin therapies are necessary 
especially for those who have a 10-year ASCVD risk of 7.5% or higher; however, our 
study showed that only 30~40% of high risk groups (≥7.5%) have received such 
treatment. If statins are recommended medications for treatment of those at high ASCVD 
risk, a sufficient therapy prior to the disease incidence is required (Homer et al. 2015). 
 The present study showed gender differences in prescribing rates of stains, 
particularly for ASCVD risk score using ACC/AHA equations. Interestingly, there were 
also a gender differences in ASCVD incidence in the US adults. Based on recent 
statistics, incidences of ASCVD including stroke and heart diseases per 100,000 in the 
US adults aged 45 to 64 years were 1,010 to 2,140 in men and 420 to 890 in women 
(Lloyd-Jones et al. 2010), while corresponding rates in Korean men and women aged 40 
to 79 years were 765 and 721, respectively (Jung et al. 2015). Therefore, there were more 
than double in gender difference for ASCVD incidence in the US population, while no 
significant difference was shown in Korean. Further studies should evaluate whether 
gender differences exist between statin therapy and ASCVD incidence rates.  
 The strengths of this cohort study include a large sample size, wide age range 
and a nationwide sample. We ascertained the ASCVD events using the NHIS database. 
Koreans have good access to medical services as almost all citizens are enrolled in 
national health insurance. When MI, CHD, or stroke is diagnosed, each hospital reports 
these medical records to the Health Insurance Review & Assessment (HIRA) for 
reimbursement. Subsequently, the HIRA board evaluates the accuracy of the requested 
medical records and grants the reimbursement. The final record is then sent and stored at 
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the Korean NHIS, where they could link the ASCVD records with KHS subjects‘ 
identification numbers for research purposes. We have previously conducted validation 
studies on nonfatal MI (Kimm et al. 2012; Kim 2013) and stroke (Park et al. 2000) 
outcomes, but a validation study on mortality data has not been conducted. 
 The limitations of this study include possible measurement errors: clinical data 
from the health promotion centers were one-time measurements of blood pressure and 
other medical outcomes. In addition, the KHS data have limitations of using a non-
population-based sample for validating a risk estimator. We have compared the 
demographic characteristics of KHS subjects with subjects of a nationally representative 
data, the KNHANES (Jee et al, 2014). General ASCVD risk factors, such as blood 
pressure and cholesterol, did not differ between the two datasets, but educational level of 
KHS subjects was about two years higher than those in the KNHANES. Therefore, 
results using KHS subjects should be interpreted with caution. 
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VI. CONCLUSIONS 
 
 The ACC/AHA 2013 Pooled Cohort Equations
 
overestimate the 10-year risk of 
ASCVD for KHS participants, and should not be directly incorporated into estimates of 
ASCVD risk in a Korean population. Recalibration of the ACC/AHA Equations corrects 
the overestimation and, thus, can be a useful approach for the generalization of the 
ACC/AHA Equations
 
in other populations. We also developed an ASCVD prediction 
model for Koreans and compared the estimates from the model with the actual ASCVD 
cases. This KRPM provides an accurate prediction of the 10-year ASCVD risk among 
Koreans in our study population. However, 10 year ASCVD risk scores using ACC/AHA 
and KPRM equations showed moderate associations with prescribing rates of statins. 
This risk algorithm should be further tested in another validation cohort before it 
could be generalized across Korea as an ASCVD risk assessment tool.  
 We hope that utilization of prediction equations can enhance ASCVD prevention 
and management through accurate risk stratification. This will subsequently provide a 
more accurate allocation of preventive therapies and improved control of ASCVD risk 
factors such as hypertension, hypercholesterolemia, and diabetes. 
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APPENDIX 
 
A.1. Recalibrated ACC/AHA 2013 Pooled Cohort Equations Risk Score for ASCVD 
(White) 
 
Hazard ratios (exponential regression coefficients) are shown in Table 3, 4. From these, a 
linear equation was constructed to produce the risk score.  
 
For men, the risk score (RACC-WM) is defined using the following steps: 
RAC-WM = 12.344 × AGE + 11.853 × TC – 2.664 × AGETC – 7.990 × HDL + 1.769 × 
AGEHDL + 1.797 × TRSBP + 1.764 × UNSBP + 7.837 × CUSMOK – 1.795 × 
LAGESMOK + 0.658 × DM 
RWMSUM = 12.344 × 3.902 + 11.853 × 5.263 – 2.664 × 20.538 − 7.990 × 3.847 + 1.769 
× 15.014 + 1.797 × 0.262 + 1.764 × 4.555 + 7.837 × 0.496 − 1.795 × 1.923 + 0.658 × 
0.101 
x =RAC-WM − RWMSUM 
y = exp(x). Finally, the absolute 10-year risk of ASCVD, RACC_WM = (1 – 0.97609y), 
where 0.97609 is the baseline survival rate for men. 
 
For women, the risk score (RACC-WW) is defined similarly. 
RAC-WW = −29.799 × AGE + 4.884 × AGESQ + 13.540 × TC – 3.114 × AGETC – 
13.578 × HDL + 3.149 × AGEHDL + 2.019 × TRSBP + 1.957 × UNSBP + 7.574 × 
CUSMOK – 1.665 × LAGESMOK + 0.661 × DM 
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RWWSUM = −29.799 × 3.935 + 4.884 × 15.507 + 13.540 × 5.284 – 3.114 × 20.801 – 
13.578 × 3.965 + 3.149 × 15.600 + 2.019 × 0.329 + 1.957 × 4.483 + 7.574 × 0.045 – 
1.665 × 0.177 + 0.661 × 0.072 
x = RAC-WW − RWWSUM 
y = exp(x). Finally, the absolute 10-year risk of ASCVD, RACC_WW = (1 − 0. 98479y), 
where 0. 98479 is the baseline survival rate for women.
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Appendix A.2. Recalibrated ACC/AHA 2013 Pooled Cohort Equations Risk Score 
for ASCVD (African-American) 
 
Hazard ratios (exponential regression coefficients) are shown in Table 3, 4. From these, a 
linear equation was constructed to produce the risk score.  
 
For men, the risk score (RACC-AM) is defined using the following steps: 
RAC-AM = 2.469 × AGE + 0.302 × TC – 0.307 × HDL + 1.916 × TRSBP + 1.809 × 
UNSBP + 0.549 × CUSMOK + 0.645 × DM 
RAMSUM = 2.469 × 3.902 + 0.302 × 5.263 – 0.307 × 3.847 + 1.916 × 0.262 + 1.809 × 
4.555 + 0.549 × 0.496 + 0.645 × 0.101 
x =RAC-AM − RAMSUM 
y = exp(x). Finally, the absolute 10-year risk of ASCVD, RACC_AM = (1 − 97609y), 
where 97609 is the baseline survival rate for men. 
 
For women, the risk score (RACC-AW) is defined similarly. 
RAC-AW = −17.114 × AGE + 0.940 × TC – 18.920 × HDL + 4.475 × AGEHDL + 
29.291 × TRSBP – 6.432 × AGETRSBP + 27.820 × UNSBP – 6.087 × AGEUNSBP + 
0.691 × CUSMOK + 0.874 × DM 
RAWSUM = −17.114 × 3.935 + 0.940× 5.284 – 18.920 × 3.965 + 4.475 × 15.600 + 
29.291 × 0.329 – 6.432 × 1.326 + 27.820 × 4.483 – 6.087 × 17.616 + 0.691 × 0.045 + 
0.874 × 0.072 
x = RAC-AW − RAWSUM 
y = exp(x). Finally, the absolute 10-year risk of ASCVD, RACC_AW = (1 − 0. 98479y), 
where 0.98479 is the baseline survival rate for women. 
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Appendix B. Korean Risk Score for ASCVD 
 
Hazard ratios (exponential regression coefficients) are shown in Table 5. From these, a 
linear equation was constructed to produce the risk score.  
For men, the risk score (KRS-M) is defined using the following steps: 
KMSUM = 9.362 × AGE + 2.425 × AGESQ + 6.409 × TC − 1.430 × AGETC −3.843 × 
HDL + 0.810 × AGEHDL + 18.589 × TRSBP − 4.116 × AGETRSBP + 18.541 × 
UNSBP − 4.112 × AGEUNSBP + 2.464 × CUSMOK − 0.503 × LAGESMOK + 0.410 × 
DM 
Where AGESQ is the square of age, TC is total cholesterol, HDL is HDL-cholesterol, 
TRSBP is treated systolic blood pressure, UNSBP is untreated systolic blood pressure, 
CUSMOK is current smoker and DM is diabetes. All variables except for smoking status 
and diabetes were used as the log format. When an age interaction is present with lipids 
or BP, the natural log of age is multiplied by the natural log of the lipid or BP and the 
result is multiplied by the parameter estimate.  
MSUM = 9.362 × 3.902 + 2.425× 15.253 + 6.409× 5.263 − 1.430× 20.538 − 3.843 × 
3.847 + 0.810 × 15.014 + 18.589 × 0.262 − 4.116 × 1.049 + 18.541 × 4.555 − 4.112 × 
17.754 + 2.464 × 0.496 − 0.503 × 1.923 + 0.410 × 0.101  
x =KMSUM − MSUM 
y = exp(x). Finally, the absolute 10-year risk of ASCVD, KRS_M = (1 − 0.96427y), 
where 0.97609 is the baseline survival rate for men. 
 
For women, the risk score (KRS-W) is defined similarly. 
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KWSUM = −9.519 × AGE + 3.417 × AGESQ + 0.320 × TC – 0.476 × HDL + 13.402 × 
TRSBP – 2.889 × AGETRSBP + 13.291 × UNSBP – 2.876 × AGEUNSBP + 0.415 × 
CUSMOK + 0.424 × DM 
WSUM = −9.519 × 3.935 + 3.417 × 15.507 + 0.320 × 5.284 − 0.476 × 3.965 + 13.402 × 
0.329 − 2.889 × 1.326 + 13.291 × 4.483 − 2.876 × 17.616 + 0.415 × 0.045 + 0.424 × 
0.072 
x = KWSUM − WSUM 
y = exp(x). Finally, the absolute 10-year risk of ASCVD, KRS_W = (1 − 0.96963y), 
where 0.98479 is the baseline survival rate for women. 
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ABSTRACT IN KOREAN 
 
한국인 심뇌혈관 예측 모형 개발과 스타틴 처방율 
 
연세대학교 대학원 보건학과 
정 금 지 
 
배경 및 목적 
본 연구의 목적은 미국 심장병 학회/미국 심장협회 (American College of 
Cardiology/American Heart Association, ACC/AHA)에서 만든 심뇌혈관 질환의 
예측모형 (이하 미국 심뇌혈관 질환 예측모형)을 한국인 심장병 연구 (Korean 
Heart Study, KHS) 대상자에게 적용 하여 평가하고, 한국인 예측 모형 (Korean 
Risk Prediction Model, KRPM)을 개발하고 예측력을 평가하고자 하였다, 또한 
이 두 가지의 심뇌혈관 예측 모형으로부터 한국인 일반 인구를 대상으로 
10 년 심뇌혈관 위험 점수를 산출하여 이에 따른 지난 10 년간 (2004-2013)의 
스타틴 처방율을 살펴보고자 하였다. 
 
연구 방법 
한국인 심장병 연구 대상자 중에서 심뇌혈관 기저질환이 없는 40-
79 세의 200,010 명이 대상자로 선정되었다. 한국인 심장병 연구에서 미국 
심뇌혈관 질환 예측모형의 구별성 능력과 정확성 능력 검정을 시행하였다. 
미국 심뇌혈관 질환 예측모형의 재정확성 분석은 미국 심뇌혈관 질환 
예측모형의 회귀계수와 한국인 심장병 연구 코호트에서 산출된 위험 
요인들의 평균값과 심뇌혈관 질환의 발생률을 이용하였다. 한국인 예측 모형 
개발은 한국인 심장병 연구 코호트에서 산출된 회귀계수, 위험 요인들의 
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평균값과 심뇌혈관 질환의 발생률을 이용하였다. 또한 각 모형의 누적 
발생율을 이용 하여 스타틴 처방율을 계산하였다. 
 
연구 결과 
구별성 능력 검정에서는 미국 심뇌혈관 질환 예측모형에서는 백인 
모형과 흑인모형 모두에서 질병이 발생한 사람과 그렇지 않은 경우를 
구별하는 능력이 중간 정도였으며, 이는 한국인 예측 모형과 유사하였다. 
남자의 경우, AUROC 값이 0.727 (백인 모델), 0.725 (흑인 모델), 0.741 
(한국인 모델) 이었으며, 여자의 경우 0.738 (백인 모델), 0.739 (흑인 모델), 
0.745 (한국인 모델) 였다. 남자의 경우 심뇌혈관질환 10 년 위험도는 백인 
모델에서 56.5%, 흑인 모델에서 74.1% 과대 추정되었고, 여자의 경우 
백인모델에서 27.9%, 흑인 모델에서 29.1% 과대 추정되었다. 재보정된 미국 
심뇌혈관 질환 예측모형에서 구별성 능력 검정은 큰 차이가 없었으나 남자의 
백인 모델에서 정확성 검정력이 다소 향상되었다. 세가지 심뇌혈관 예측 
모형에서 한국인 예측 모형이 부표본 확인 연구에서 남녀 모두 가장 낮은 
Hosmer-Lemshow 카이 제곱 값을 보이면서 가장 좋은 정확성 검정력을 보였다. 
추적 관찰 기간 동안 스타틴 처방율은 남자 26.3% 여자 33.5%를 보였다. 
 
결론 
한국인 예측 모형이 심뇌혈관 질환의 위험 예측력이 가장 좋았으며, 미국 
심뇌혈관 질환 예측모형은 한국인에게 직접 적용할 수 없었다. 그러므로 
예방적인 스타틴 치료를 결정하는데 있어 한국인 예측 모형이 도움을 줄 수 
있을 것으로 기대된다. 
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